Jiping Wang

Jiping Wang is a surgical oncologist at Brigham and Women's Hospital and Harvard Medical School with specialized expertise in the surgical treatment of colorectal cancer with peritoneal and hepatic metastasis, including cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical and research program focuses on optimizing patient selection, surgical technique, and multimodal management for patients with metastatic colorectal cancer affecting the peritoneum and liver. Colorectal cancer peritoneal metastasis (CRC-PM) historically carried a dismal prognosis, with a median survival measured in months when treated with systemic chemotherapy alone. The development of CRS-HIPEC — in which all macroscopic peritoneal disease is surgically resected (cytoreduction), followed by direct instillation of heated chemotherapy into the abdominal cavity to eliminate microscopic residual disease — has transformed outcomes for carefully selected patients. Wang has contributed to defining the patient selection criteria, technical standards, and prognostic indices that determine who benefits most from this intensive surgical procedure. Wang's research has addressed peritoneal cancer index (PCI) scoring, completeness of cytoreduction, and the association of these factors with long-term survival outcomes in CRC-PM patients undergoing CRS-HIPEC. His work has helped establish the benchmarks for acceptable morbidity and mortality of this complex procedure at high-volume centers, and has supported the development of standardized treatment pathways. He also investigates the role of systemic therapy — including bevacizumab and EGFR-targeted agents — in neoadjuvant and adjuvant settings to optimize responses before and after CRS-HIPEC. Beyond peritoneal metastasis, Wang's program encompasses colorectal cancer liver metastasis (CRLM), including parenchyma-sparing hepatectomy techniques, two-stage hepatectomy with portal vein embolization for future liver remnant augmentation, and strategies for converting initially unresectable liver disease to resectable through systemic therapy. His research evaluates outcomes of hepatic resection, ablation, and combined modality therapy in CRLM. Wang is affiliated with the Multi-Institutional Program in Peritoneal Surface Oncology and participates in collaborative national and international research networks to advance evidence-based treatment for peritoneal surface malignancies.

Jiping Wang 是布莱根妇女医院和哈佛医学院的外科肿瘤学家，专注于结直肠癌腹膜和肝转移的外科治疗，包括细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）。 Wang 在明确结直肠癌腹膜转移患者行CRS-HIPEC的患者选择标准、腹膜癌症指数（PCI）评分体系和细胞减灭完整性与长期生存关系方面做出了重要贡献。他的研究还涵盖结直肠癌肝转移的保留肝实质肝切除术、分阶段肝切除配合门静脉栓塞以及系统治疗转化策略，推动了多模式综合治疗标准的建立。